卡介苗膀胱灌注用于中高危NMIBC患者治疗的有效性和安全性:一项真实世界研究  

Real-world study of efficacy and safety of BCG intravesical treatment for intermediate-and high-risk NMIBC

作　　者：赵子懿 吴玉伟 李明东 张朋[1] ZHAO Ziyi;WU Yuwei;LI Mingdong;ZHANG Peng(Department of Urology,West China Hospital,Sichuan University,Chengdu,610041,China)

机构地区：[1]四川大学华西医院泌尿外科,成都610041

出　　处：《临床泌尿外科杂志》2023年第12期910-914,920,共6页Journal of Clinical Urology

基　　金：四川省重点研发项目(No:2023YFS0315)。

摘　　要：目的:评价真实世界的卡介苗膀胱灌注治疗中高危非肌层浸润性膀胱癌(non-muscle invasive bladder cancer,NMIBC)的疗效与安全性。方法:回顾性收集2014年6月—2020年10月四川大学华西医院收治的398例行经尿道膀胱肿瘤切除术(transurethral resection of bladder tumor,TURBT)患者的临床特征、治疗效果、安全性及生存数据并进行统计学分析。结果:卡介苗膀胱灌注治疗中高危NMIBC患者的复发率为30.7%,1、3、5年无复发累积生存率分别为83.9%、71.6%、67.3%。3级及以上(CTCAE5.0)不良反应发生率为4.5%。结论:卡介苗膀胱灌注治疗中高危NMIBC是一项安全且有效的治疗措施。Objective To evaluate the efficacy and safety of intravesical BCG treatment for intermediate-and high-risk NMIBC in a real-world study.Methods We retrospectively analyzed the real-world clinical research data.The clinical characteristics,therapeutic efficacy,safety and survival data of 398 TURBT patients admitted to West China Hospital from June 2014 to October 2020 were statistically analyzed by SPSS software.Results The recurrence rate of intermediate-and high-risk NMIBC patients treated with intravesical BCG was 30.7%,and the 1-year,3-year and 5-year recurrence-free cumulative survival rates were 83.9%,71.6%and 67.3%,respectively.The occurrence of adverse effects of grade 3;4(CTCAE 5.0)was 4.5%.Conclusion Intravesical perfusion with BCG is safe and effective in the treatment of intermediate-and high-risk NMIBC.

关 键 词：非肌层浸润性膀胱癌 卡介苗 复发 进展 真实世界研究 

分 类 号：R737.14[医药卫生—肿瘤]